In New York state, eXoZymes, Inc. announced that CEO Michael Heltzen was joined by eXoZymes team members to ring the Nasdaq Stock Market closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at $8 per share, which closed on November 14, 2024.
“Our team is thrilled to be ringing the closing bell to commemorate both our initial public offering and our significant progress towards establishing that after synthetic biology (SynBio) we’re now entering the exozymes era of biotechnology,” said CEO of eXoZymes, Michael Heltzen. “We appreciate the continued support of all our stakeholders and look forward to sharing our commercial milestones soon, as we unleash the power of our platform to rapidly transform affordable and widely available feedstocks into a diverse range of valuable chemicals at industrial scale.”
